Skip to Content

Raghavan Murugan Awarded R01 to Study Biomarkers in Contrast-Induced Acute Kidney Injury

Sun, 10/23/2016

Many patients with chronic kidney disease will undergo angiography, a routine diagnostic procedure that involves injecting a dye, or contrast material, into the bloodstream so as to perform an x-ray of blood vessels. An unfortunate side effect of the procedure is that a third of these patients will develop contrast-induced acute kidney injury (CIAKI), which is difficult to detect early on. Moreover, nearly 20% of these patients with CIAKI are at further risk for developing subsequent cardiovascular disease.

(L to R) John Kellum, Raghavan Murugan, Steven Weisbord, Paul Palevsky, Ali Smith; (Inset) Joyce Chang

Identifying potential aids, in particular urinary biomarkers, which can be used to predict the outcomes for a particular patient undergoing angiography, is the subject of a new study from researchers in The Center for Critical Care Nephrology, CRISMA Center, Department of Critical Care Medicine. Raghavan Murugan, MD, MS, FRCP, FCCM, an Associate Professor of Critical Care Medicine and Clinical and Translational Science, will be the principal investigator on the study titled, “The Biomarker Effectiveness Analysis in Contrast Nephropathy” or BEACON, which has just been funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The study (#R01DK106256) will run from 2016 to 2021.

Recent research has shown that two novel, highly sensitive, urinary cell cycle arrest biomarkers can quickly indicate that a patient may be at risk for developing acute kidney injury (AKI). BEACON will seek to investigate whether these same biomarkers can be used to predict renal and cardiovascular outcomes in patients undergoing angiography. Leveraging an ongoing comparative effectiveness study funded by the Department of Veterans Affairs testing several substances that may help prevent CIAKI, along with a biorepository funded by the NIDDK, BEACON will test 1100 subjects on whether these biomarkers can predict outcomes such as mortality, dialysis dependence, progression of chronic kidney disease, or other cardiovascular complications at 90 days after the procedure. If successful, the study could have a significant impact on clinical practice.

Other BEACON co-investigators include Drs. Steven Weisbord, Paul Palevsky, John Kellum, and Joyce Chang. Ms. Ali Smith will be the project manager.